HIV vaccine development in the aftermath of the STEP study: re-focus on occult HIV infection?
about
Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic ApplicationsCellular superspreaders: an epidemiological perspective on HIV infection inside the bodyOral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses.Acute mucosal pathogenesis of feline immunodeficiency virus is independent of viral dose in vaginally infected cats.Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.Designer antigens for elicitation of broadly neutralizing antibodies against HIV.Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study.Interleukin-encoding adenoviral vectors as genetic adjuvant for vaccination against retroviral infectionRisk of immunodeficiency virus infection may increase with vaccine-induced immune response.Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency.HLA and infectious diseases.Strategies to overcome host immunity to adenovirus vectors in vaccine development.Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells.The two faces of vaccine-induced immune response: protection or increased risk of HIV infection?!The STEP study provides a hint that vaccine induction of the right CD8+ T cell responses can facilitate immune control of HIV.
P2860
Q26776553-0F931B05-65CB-49B5-8A12-50577A11F58BQ28657772-09A75DCF-BAA4-435C-9451-5176C17118CBQ33686890-3DB7202C-FD13-4A6D-B18C-A847A348FE6DQ33715758-122EB044-73FD-4935-B00E-3BB213F1BC22Q33819656-3489143D-00F3-46F6-906D-209D3806F79DQ34511575-EFD07833-45F5-4F49-8883-041DFF453B61Q34673391-42D3FB92-6142-4DE6-9925-AD6FA34EA9EEQ35070346-9B1A82B6-0B32-409E-9098-9DB5DBE54EA4Q36276637-B48A3BE6-B362-469A-A6C3-500FD6E18B5AQ37154783-4FFD191A-B5D2-4A8E-A752-5E17804952AEQ37444410-B8172E5B-8967-488B-A84D-B6EF6C00FE14Q37503253-E30653C8-0B57-43C1-BA74-AE412B7590C3Q38827936-666C622D-BB2E-4929-AD28-2DD4D3480BF0Q42241791-93A2DB16-77C4-4A62-837B-AF33F9C2FE6AQ42710662-2BC821A5-2C24-415A-B3EF-8BB1A52188A0
P2860
HIV vaccine development in the aftermath of the STEP study: re-focus on occult HIV infection?
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
HIV vaccine development in the ...... focus on occult HIV infection?
@ast
HIV vaccine development in the ...... focus on occult HIV infection?
@en
type
label
HIV vaccine development in the ...... focus on occult HIV infection?
@ast
HIV vaccine development in the ...... focus on occult HIV infection?
@en
prefLabel
HIV vaccine development in the ...... focus on occult HIV infection?
@ast
HIV vaccine development in the ...... focus on occult HIV infection?
@en
P2860
P921
P1433
P1476
HIV vaccine development in the ...... focus on occult HIV infection?
@en
P2860
P304
P356
10.1371/JOURNAL.PPAT.1000114
P50
P5008
P577
2008-08-29T00:00:00Z